Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$846,595 $661,982

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Twelve Months Twelve Months

Ended Ended

December 31, 2008 December 31, 2009

Projected GAAP basic income per common

share $4.41 - $4.51 $4.95 - $5.05

Amortization of current intangibles $1.48 - $1.48 $1.36 - $1.36

Accelerated depreciation adjustment-

CIMA $0.10 - $0.10 $0.09 - $0.09

Accelerated depreciation adjustment-

Mitry-Mory $0.10 - $0.10 $0.24 - $0.24

Cost of goods sold adjustments $0.38 - $0.38 $- - $-

Research and development adjustments $0.12 - $0.12 $- - $-

Selling, general and administrative

adjustments $0.44 - $0.44 $- - $-

Settlement reserve adjustments $0.11 - $0.11 $- - $-

In-process research and development

adjustment $0.15 - $0.15 $- - $-

Restructuring adjustments $0.12 - $0.12 $0.07 - $0.07

Interest expense adjustment $0.17 - $0.17 $- - $-

Interest expense adjustment for

APB 14-1 $- - $- $0.63 - $0.63

Tax effect of pre-tax adjustments at

the applicable tax rates $(2.38)- $(2.38) $(0.84)- $(0.84)

Basic adjusted income per common share

guidance $5.20 - $5.30 $6.50 - $6.6
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... Calif. , May 23, 2013 Virobay, ... treatment for pain has reached an important milestone, as ... of VBY-036 - a selective cathepsin S inhibitor.   ... is a double-blind, randomized, placebo-controlled study designed to evaluate ... of VBY-036 in healthy adults. "The initiation ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... in STEM industries, Black Data Processing Associates (BDPA), is ... on June 8, 2013. This all-day event will encourage ... and learn the ins and outs from many of ... 3 p.m. at the New Jersey Institute of Technology, ...
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... in Scotland, which boasts more than 380,000 visitors annually, ... powered by the Freedom® portable driver as part ... most advanced exhibitions of its kind. , “BodyWorks ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced ... of,the inaugural companies in the new NASDAQ(R) NeuroInsights(R) ... an index designed to track,the performance of selected ... three major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech ...
... MacroGenics, Inc. announced,today that Mr. Jeffrey H. Buchalter ... of Directors. With more than 20 years of ... and,biotechnology industry, Mr. Buchalter is well poised to ... company matures toward,commercializing its pipeline. "We are ...
... York, September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: ... on September 24, 2007, the Company received a ... comply with the minimum,$10 million shareholders, equity requirement ... set forth in Marketplace Rule 4450(a)(3), and that,its ...
Cached Biology Technology:Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... 22, 2013 U.S. Forest Service scientists are part ... funding from the TKF Foundation, will examine how collaborative ... individuals recover from tragedy. , The TKF Foundation announced ... projects selected for grant funding. In addition to research ... in recovery and resiliency, the 3-year, $585,000 grant will ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... and researchers at John Theurer Cancer Center at HackensackUMC, one ... latest findings in blood-cancer research at the 2012 American Society ... 1-5. Their involvement in these studies is part of John ... "We are proud to make a contribution ...
... According to a new study, children exposed to ... at increased risk for chromosomal aberrations (CAs), which have ... a potentially more harmful and long-lasting subtype of CAs. ... Health (CCCEH) at the Mailman School of Public Health, ...
... Therapeutics Centre (ETC) under the Agency for Science and Technology ... has enabled the successful development of the most comprehensive and ... this highly advanced kit, doctors can now rapidly detect all ... with almost 100% accuracy, within a few hours. This is ...
Cached Biology News:John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
Biology Products: